Pfizer's Strategic Issues

Paper Summary:

The paper examines how two major players in the pharmaceutical industry, AstraZeneca and Novartis, transformed their weaknesses and threats into strengths and opportunities, while focusing on differentiation for a competitive advantage. The paper uses these strategies to recommend a plan for Pfizer to be able to remain a strong competitor in the field of pharmaceutical research and development.

Outline:
Introduction
Issues and Strategies
AstraZeneca
Novartis
Opportunities for Pfizer
Conclusion

From the Paper:

"AstraZeneca believes a weaknesses is "exposure to 'me too' and 'indirect' competition" (Marketline, 2008). This weakness results from several companies working on drugs of the same classification or mechanism of action. Like Pfizer, AstraZeneca has a top selling statin, Crestor, for cholesterol reduction. To circumvent competition for this statin, AstraZeneca "has initiated clinical trials in a bid to highlight any benefits Crestor holds over the current market leader" which is Pfizer (Marketline, 2008). At present, AstraZeneca studies have demonstrated that their drug provides benefit to patients that other drugs in this same classification lack. Through product differentiation, AstraZeneca continues to drive sales growth."

Sample of Sources Used:

• AstraZeneca and Bristol-Myers Squibb announce expansion of worldwide collaboration todevelop and commercialize Dapagliflozin in Japan. (2009). Retrieved June 6, 2009 from http://www.astrazeneca.com/?itemId=4369714
• AstraZeneca PLC overview. (2008). Retrieved June 6, 2009 from http://www.marketlineinfo.com.ezproxy.apollolibrary.com/library/DisplayContent.aspx?R=92ABA271-D51E-4739-8ABE-969E4539D34D&N=4294837662
• Environmental analysis. (2009). Retrieved May 30, 2009 from http://business.com
• Environmental analysis. (2009). Retrieved May 30, 2009 from http://businessmanagement.com
• Ethical promotion of pharmaceuticals. (2005). Retrieved June 7, 2009 from http://www.corporatecitizenship.novartis.com/downloads/business-conduct/Ethical-Promotion-Pharmaceuticals.pdf

More papers on Pfizer's Strategic Issues:

• Analytical Essay # 125501 : "Strategic Issues at Merrill Lynch"
• Analytical Essay # 149613 : "Managing IT Strategic Issues and Management Decisions"
• Essay # 97673 : "Strategic Issues of Nike"

APA Citation:

MLA Citation: